Is the use of albumin in colloid prime solution of cardiopulmonary bypass circuit justified?
- 30 September 2001
- journal article
- clinical trial
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 72 (3) , 850-853
- https://doi.org/10.1016/s0003-4975(01)02816-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Albumin in the cardiopulmonary bypass prime: how little is enough?Perfusion, 1999
- Safety of human albumin as a constituent of biologic therapeutic productsTransfusion, 1998
- The effect of albumin priming solution on platelet activation during experimental long-term perfusionPerfusion, 1998
- Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypassEuropean Journal of Cardio-Thoracic Surgery, 1997
- A Comparative Review of Crystalloid, Albumin, Pentastarch and Hetastarch as Perfusates for Cardiopulmonary BypassThe Journal of ExtraCorporeal Technology, 1997
- Réactions anaphylactoïdes aux substituts colloïdaux du plasma : incidence, facteurs de risque, mécanismes: Enquête prospective multicentrique françaiseAnnales Françaises dʼAnesthésie et de Réanimation, 1994
- Differential surface binding of albumin, immunoglobulin G and fibrinogenBiomaterials, 1994
- On the inhibitory effect of albumin on platelet aggregationThrombosis Research, 1980
- INCIDENCE AND SEVERITY OF ANAPHYLACTOID REACTIONS TO COLLOID VOLUME SUBSTITUTESPublished by Elsevier ,1977